MARKET IS CLOSED
Loading latest tickers...
Market Indices
S&P 500
$7,722.72
+0.73%
NASDAQ 100
$30,807.93
+1.00%
DOW JONES
$51,177.00
+0.49%
NASDAQ Composite
$27,190.86
+1.19%
RUSSELL 2000
$2,815.20
+0.90%
CBOE VIX
$15.31
-6.59%
Sector Heatmap
Technology+1.01%
Financials+0.06%
Healthcare-0.01%
Consumer Cycl+1.13%
Consumer Staples+0.25%
Energy+0.40%
Industrials+0.78%
Materials+0.66%
Real Estate+0.32%
Utilities+0.38%
Comm Services+0.35%
GALT — Galectin Therapeutics Inc.
NasdaqGalectin Therapeutics Inc.
$3.90
+0.14(+3.72%)
- O
- 3.82
- H
- 3.94
- L
- 3.75
- V
- 211.65K
⏱️ End-of-day dataAs of Oct 2, 2026
Chart
About GALT
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
IndustryPHARMACEUTICAL PREPARATIONS
SectorNot available
IPO DateSep 4, 2002
Employees9
Stock ExchangeNasdaq
Ticker SymbolGALT
Key Financial Statistics
| Market Cap | $393.31M |
| P/E Ratio | N/A |
| Dividend Yield | None |
| EPS | N/A |
| Beta | N/A |
| 52-Week Range | $2.03 - $7.13 |
| 52-Week Avg Volume | 455.0K |
| VWAP | $3.89 |
| Transactions | 2,239 |
| Total Recorded Bars | 6,060 days |